Table 3.

Odds ratios and 95% confidence intervals of esophageal cancer by duration of use of statins

	Case/N	Crude odds ratio (95% CI)	Adjusted odds ratio† (95% CI)
Non-use of statins as a reference	500/2,458	1.00 (reference)	1.00 (reference)
Atorvastatin
All	19/133	0.65 (0.40–1.07)	0.52 (0.30–0.92)
< 6 months	10/68	0.68 (0.34–1.33)	0.57 (0.27–1.21)
6–11 months	6/20	1.68 (0.64–4.39)	1.86 (0.66–5.24)
≥ 12 months	3/45	0.28 (0.09–0.91)	0.14 (0.04–0.56)
Simvastatin
All	20/103	0.94 (0.57–1.55)	0.79 (0.44–1.40)
< 6 months	18/55	1.91 (1.08–3.38)	1.67 (0.86–3.25)
6–11 months	0/20	–	–
≥ 12 months	2/28	0.30 (0.07–1.27)	0.21 (0.04–1.01)
Lovastatin
All	13/84	0.72 (0.39–1.31)	0.60 (0.30–1.18)
< 6 months	8/57	0.64 (0.30–1.35)	0.50 (0.21–1.16)
6–11 months	3/14	1.07 (0.30–3.84)	1.29 (0.34–5.00)
≥ 12 months	2/13	0.71 (0.16–3.22)	0.48 (0.08–2.95)
Fluvastatin
All	9/46	0.95 (0.46–1.99)	0.81 (0.35–1.86)
< 6 months	5/30	0.78 (0.30–2.06)	0.65 (0.22–1.92)
6–11 months	1/7	0.65 (0.08–5.43)	0.58 (0.05–6.82)
≥ 12 months	3/9	1.96 (0.49–7.86)	1.68 (0.33–8.49)
Pravastatin
All	4/29	0.63 (0.22–1.81)	0.50 (0.16–1.61)
< 6 months	3/22	0.62 (0.18–2.10)	0.57 (0.15–2.19)
6–11 months	0/3	–	–
≥ 12 months	1/4	1.31 (0.14–12.6)	1.26 (0.12–13.8)
Rosuvastatin
All	4/28	0.65 (0.23–1.89)	0.37 (0.11–1.21)
< 6 months	2/17	0.52 (0.12–2.29)	0.25 (0.05–1.30)
6–11 months	1/3	1.96(0.18–21.6)	1.33 (0.11–16.3)
≥ 12 months	1/8	0.56(0.07–4.56)	0.35 (0.04–3.61)

^†Adjusted for age, sex, esophageal diseases, alcoholism, statins, proton pump inhibitors, histamine-2 receptor antagonists, other NSAIDs, and COX-2 inhibitors.